Combined bone scintigraphy and fluorocholine PET/computed tomography predicts response to radium-223 therapy in patients with prostate cancer
Aim: To assess the value of bone scintigraphy and 18F-fluorocholine PET/computed tomography (CT) in predicting outcome in patients with prostate cancer and bone metastases treated with 223radium. Materials & methods: Retrospective analysis of 48 patients that underwent 223radium therapy. End poi...
Saved in:
| Main Authors: | Michele Klain, Valeria Gaudieri, Mario Petretta, Emilia Zampella, Giovanni Storto, Carmela Nappi, Carlo Buonerba, Felice Crocetto, Rosj Gallicchio, Fabio Volpe, Leonardo Pace, Martin Schlumberger, Alberto Cuocolo |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-09-01
|
| Series: | Future Science OA |
| Subjects: | |
| Online Access: | https://www.future-science.com/doi/10.2144/fsoa-2021-0053 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
RADIUM-223. PLACE IN THE TREATMENT OF METASTATIC CASTRATION-REFRACTORY PROSTATE CANCER
by: A. A. Kostin, et al.
Published: (2017-12-01) -
Quantifying the survival benefit of completing all the six cycles of radium-223 therapy in patients with castrate-resistant prostate cancer with predominant bone metastases
by: John Buscombe, et al.
Published: (2021-04-01) -
Bilateral neovascular glaucoma associated with Radium-223 infusions for prostate cancer
by: Chelsea M. Viscardi, et al.
Published: (2024-12-01) -
Clinical Outcome Patterns of Use of Radium-223 in Patients with Metastatic Castration-Resistant Prostate Cancer
by: Colleen Mackenzie, et al.
Published: (2024-10-01) -
Factors Influencing Outcome Post–Radium-223 Dichloride in Castrate Resistant Prostate Cancer: A Review of Some Real-World Challenges
by: Amit Bhoil, et al.
Published: (2022-12-01)